Increased Levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis

Carcinogenesis

Volumn 17, Issue 12, 1996, Pages 2581-2587

  Farinati, F ^c,f   Herszenyi L ^a   Plebani, M ^b   Carraro, P ^b   De Paoli, M ^b   Cardin, R ^a   Roveroni, G ^b   Rugge, M ^c   Nitti, D ^d   Grigioni, W F ^e   D'Errico, A ^e   Naccarato, R ^a  

^a Istituto di Medicina Interna   (Italy)

^b Laboratorio Centrale   (Italy)

^c Istituto di Anatomia Patologica   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Istituto di Medicina Interna di Padova   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CATHEPSIN L; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; CANCER INVASION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH BIOPSY; STOMACH CARCINOGENESIS; STOMACH EPITHELIUM;

ADULT; AGED; AGED, 80 AND OVER; CATHEPSIN B; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; ENDOPEPTIDASES; FEMALE; GASTRITIS, ATROPHIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; STOMACH NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR;

EID: 12644288323     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.12.2581     Document Type: Article

References (60)

1. Nigam,A.K., Pignatelli,M. and Boulos,P.B. (1994) Current concepts in metastasis. Gut, 35, 996-1000.
2. Mason,R.W., Johnson,D.A., Barrett,A.J. and Chapman,H.A. (1986) Elastinolytic activity of human cathepsin L. Biochem. J., 233, 925-927.
3. Okoda,Y. and Yokota,Y. (1990) Purification and properties of cathepsin B from sea urchin eggs. Comp. Biochem. Physiol., 96, 381-386.
4. Sloane,B.F. (1990) Cathepsin B and cystatins: evidence for a role in cancer progression. Semin. Cancer Biol., 1, 137-152.
5. Ohta,T., Terada,T., Nagakawa,T., Tajima,H., Itoh,H., Fonseca,L. and Miyazaki,I. (1994) Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br. J. Cancer, 69, 152-156.
6. Shuja,S., Sheahan,K. and Murnane,M.J. (1991) Cysteine endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. Int. J. Cancer, 49, 341-346.
7. Dano,K., Andreasen,P.A., Grondahl-Hansen,J., Kristensen,P., Nielsen,L.S. and Skriver,L. (1985) Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44, 139-266.
8. Saksela,O. and Rifkin,D.B. (1988) Cell-associated plasminogen activation: regulation and physiological functions. Ann. Rev. Cell Biol., 4, 93-126.
9. Markus,G. (1988) The relevance of plasminogen activators to neoplastic growth - a review of recent literature. Enzyme, 40, 158-172.
10. Nishino,N., Aoki,K., Tokura,Y., Sakaguchi,S., Takada,Y. and Takada,A. (1988) The urokinase type of plasminogen activator in cancer of digestive tract. Thromb. Res., 50, 527-535.
11. Hart,I.R. and Saini,A. (1992) Biology of tumor metastasis. Lancet, 339, 1453-1457.
12. Sprengers,E.D. and Kluft,C. (1987) Plasminogen activator inhibitors. Blood, 69, 381-387.
13. Jänicke,F., Schmitt,M., Pache,L., Ulm,K., Harbeck,N., Hofler,H. and Graeff, H. (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat., 24, 195-208.
14. Bouchet,C., Spyratos,F., Martin,P.M., Hacène,K., Gentile,A. and Oglobine,J. (1994) Prognostic value of urokinase-type plasminogen activator (UPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br. J. Cancer, 69, 398-405.
15. Landau,B.J., Kwaan,H.C., Verrusio,E.N. and Brem,S.S. (1994) Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 in malignant human brain tumors. Cancer Res., 54, 1105-1108.
16. Sier,C.F.M., Verspaget,H.W., Griffioen,G., Verheien,J.H., Quax,P.H.A., Dooijewaard,G., De Bruin,P.A.F. and Lamers,C.B.H.W. (1991) Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implication of urokinase in colorectal carcinogenesis. Gastroenterology, 101, 1522-1528.
17. Kirchheimer,J.C., Huber,K., Wagner,O. and Binder,B.R. (1987) Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. Br. J. Haematol., 66, 85-89.
18. Tanaka,N., Fukao,H., Ueshima,S., Okada,K., Yasutomi,M. and Matsuo,O. (1991) Plasminogen activator inhibitor 1 in human carcinoma tissues. Int. J. Cancer, 48, 481-484.
19. Buo,L., Lyberg,T., Jorgensen,L., Johansen,H.T. and Aasen,A.O. (1993) Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. APMIS, 101, 235-241.
20. Sier,C.F.M., Vloedgraven,HJ.M., Ganesh,S., Griffioen,G., Quax,P.H.A., Verheien,J.H., Dooijewaard,G., Welvaart,K., Van de Velde,C.J.H., Lamers,C.B.H.W. and Verspaget,H.W. (1994) Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology, 107, 1449-1456.
21. Vasishta,A., Baker,P.R., Hopwood,D., Holley,P.M. and Cuschieri,A. (1985) Proteinase-like peptidase activities in malignant and non-malignant gastric tissue. Br. J. Surg., 72, 386-388.
22. Watanabe,M., Higashi,T., Watanabe,A. et al. (1989) Cathepsin B and L activities in gastric cancer tissue: correlation with histological findings. Biochem. Med. Metab. Biol., 42, 21-29.
23. Chung,S.M. and Kawai,K. (1990) Protease activities in gastric cancer tissues. Clin. Chim. Acta, 189, 205-210.
24. Takai,S., Yamamura,M., Tanaka,K., Kawanishi,H., Tsuji,M., Nakane,Y., Hioki,K. and Yamamoto,M. (1991) Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int. J. Cancer, 48, 20-27.
25. Sier,C.F.M, Verspaget,H.W., Griffioen,G., Ganesh,S., Vloedgraven,H.J.M. and Lamers,C.B.H.W. (1993) Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut, 34, 80-85.
26. Nekarda,H., Schmitt,M., Ulm,K., Wenninger,A., Vogelsang,H., Becker,K., Roder,J.D., Fink,U. and Siewert,J.R. (1994) Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res., 54, 2900-2907.
27. Plebani,M., Herszènyi,L., Cardin,R., Roveroni,G., Carraro,P., De Paoli,M., Rugge,M., Grigioni,W.F., Nitti,D., Naccarato,R. and Farinati,F. (1995) Cysteine and serine proteases in gastric cancer. Cancer, 76, 367-375.
28. De Bruin,P.A.F., Griffioen,G., Verspaget,H.W., Verheijen,J.H. and Lamers,C.B.H.W. (1987) Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps and adenocarcinomas. Cancer Res., 47, 4654-4657.
29. Farinati,F., Plebani,M., Di Mario,F. et al. (1993) Aspartic proteinases and gastrin in the diagnosis of gastric cancer and gastric precancerous changes. Eur. J. Gastroenterol. Hepatol., 5, 707-712.
30. Samloff,I.M., Varis,K., Ihamaki,T., Siurala,M. and Rotter,J.I. (1982) Relationships among serumpepsinogen I, pepsinogen II, and gastric mucosal history. Gastroenterology, 83, 204-209.
31. Miki,K., Ichinose,M., Ishikawa,K.B. et al. (1993) Clinical application of serum Pepsinogen I and II levels for mass screening to detect gastric cancer. Japan. J. Cancer Res., 84, 1086-1090.
32. Matsukura,N., Onda,M., Tokunaga,A., Fujita,I., Okuda,T., Mizutani,T., Kyono,S. and Yamashita,K. (1993) Significance of serum markers pepsinogen I and II for chronic atrophic gastritis, peptic ulcer and gastric cancer. J. Clin. Gastroenterol., 17, S146-S150.
33. Rugge,M., Baffa,R., Farinati,F., Di Mario,F., Guido,M., Valiante,F. and Ninfo,V. (1991) Epithelial dysplasia in atrophic gastritis. Bioptical follow-up study. Ital. J. Gastroenterol., 23, 70-73.
34. Correa,P. (1988) Chronic gastritis: a clinicopathologic classification. Am. J. Gastroenterol., 83, 504-509.
35. Price,A.B. (1991) The Sydney system. J. Gastroenterol. Hepatol., 6, 209-222.
36. Morson,B.C., Sobin,L.H., Grundmann,E., Johansen,A., Nagayo,T. and Serck-Hanssen,A. (1980) Precancerous conditions and epithelial dysplasia in the stomach. J. Clin. Pathol., 33, 711-721.
37. Riddel,R.H., Goldman,H., Ransohoff,D.F. et al. (1983) Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical application. Hum. Pathol., 14, 931-968.
38. Bradford,M.A. (1976) Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
39. Wodsinski,M.A., Bardhan,K.D., Reilly,J.T., Cooper,P. and Preston,F.E. (1993) Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease. Gut, 34, 1310-1314.
40. Nitti,D., Farini,R., Grassi,F. et al. (1984) Carcinoembryonic antigen in gastric cancer juice collected during endoscopy. Value in detecting high-risk patients and gastric cancer. Cancer, 52, 2334-2337.
41. Farinati,F., Nitti,D., Cardin,F., Di Mario,F., Costa,F., Rossi,C., Marchett,A., Lise,M. and Naccarato,R. (1988) CA 19-9 determination in gastric juice: role in identifying cancer and high-risk patients. Eur. J. Cancer Clin. Oncol., 24, 923-927.
42. Farinati,F., Holmgren,J., Di Mario,F. et al. (1991) CA 50 determination in body fluids: can we screen patients at risk for gastric cancer? Int. J. Cancer, 47, 7-11.
43. Saku,T., Sakai,H., Tsuda,N., Okabe,H., Kato,Y. and Yamamoto,K. (1990) Cathepsin D and E in normal, metaplastic, dysplastic, and carcinomatous gastric tissue: an immunohistochemical study. Gut, 31, 1250-1255.
44. Weiss,S.J. (1989) Tissue destruction by neutrophils. N. Engl. J. Med., 320, 365-376.
45. Furuhashi,M., Nakahara,A., Fukutomi,H., Kominami,E., Grube,D. and Uchiyama,Y. (1991) Immunocytochemical localization of cathepsins B, H, and L in the ral gastro-duodenal mucosa. Histochemistry, 95, 231-239.
46. Piotrowski,J., Czajkowski,A., Yotsumoto,F., Slomiany,A. and Slomiany,B.L. (1994) Sulglycotide effect on the proteolytic and lipolytic activities of Helicobacter pylori toward gastric mucus. Am. J. Gastroenterol., 89, 232-236.
47. Correa,P. (1988) A human model of gastric carcinogenesis. Cancer Res., 48, 3554-3560.
48. Correa,P. (1992) Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on cancer epidemiology and prevention. Cancer Res., 52, 6735-6740.
49. Sipponen,P,. Kekki,M. and Siurala,M. (1983) Atrophic chronic gastritis and intestinal metaplasia in gastric carcinoma. Cancer, 52, 1062-1068.
50. Farinati,F., Cardin,F., Di Mario,F., Valiante,F., Naccarato,R., Arslan-Pagnini,C., Rugge,M. and Baffa,R. (1989) Follow-up in gastric dysplasia patients. Am. J. Surg. Pathol., 13, 173-174.
51. Rugge,M., Farinati,F., Di Mario,F., Baffa,R., Valiante,F. and Cardin,F. (1991) Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia. Hum. Pathol., 22, 1002-1008.
52. Farinati,F., Rugge,M., Di Mario,F., Valiante,F. and Baffa,R. (1993) Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. Endoscopy, 25, 261-264.
53. Rugge,M., Farinati,F., Baffa,R., Sonego,F., Di Mario,F., Leandro,G. and Valiante,F. (1994) Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Gastroenterology, 107, 1288-1296.
54. Ming,SC., Bajtai,A., Correa,P., Elster,K., Jarvi,O.H., Munoz,N., Nagayo,T. and Stemmermann,G.N. (1984) Gastric dysplasia: significance and pathologic criteria. Cancer, 54, 1794-1801.
55. Lansdown,M., Quirke,P., Dixon,M.F., Axon,A.T. and Johnston,D. (1990) High grade dysplasia of the gastric mucosa: a marker for gastric carcinoma. Gut, 31, 977-980.
56. De Dombal,F.T., Price,A.B., Thompson,H., Williams,G.T., Morgan,A.G., Softley,A., Clamp,S.E. and Unwin,B.J. (1990) The British Society of Gastroenterology early gastric cancer/dysplasia survey: an interim report. Gut, 31, 115-120.
57. Shiao,Y.H., Rugge,M., Correa,P., Lehmann,H.P. and Scheer,W.D. (1994) p53 alteration in gastric precancerous lesions. Am. J. Pathol., 144, 511-517.
58. Correa,P. and Shiao,Y. (1994) Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res., 54(Suppl.), 1941-1943.
59. Reilly,D., Christensen,L., Duch,M.,Nolan,N., Duff,M.J. and Andreasen,P.A. (1992) Type-1 plasminogen activator inhibitor in human breast carcinomas. Int. J. Cancer, 50, 208-214.
60. Kristensen,P., Pyke,C., Lund,L.R., Andreasen,P.A. and Dano,K. (1990) Plasminogen activator inhibitor type-1 in Lewis lung carcinoma. Histochemistry, 93, 559-566.